Director/PDMR Shareholding

RNS Number : 8547Z
GlaxoSmithKline PLC
24 July 2008
 

Notification of Transactions of Directors and Persons Discharging Managerial

Responsibility



Awards made by GlaxoSmithKline

On 23 July 2008 the Company granted certain share-based awards to Directors and Persons Discharging Managerial Responsibility. The following awards were made:


  • Awards under the GlaxoSmithKline Performance Share Plan, which are subject to performance conditions; and

  • Awards under the GlaxoSmithKline Share Option Plan, which are subject to performance conditions; and


The Performance Share Plan and the Share Option Plan were both approved by shareholders on 31 July 2000, and allow awards to be made to senior executives in the Group, including the Executive Directors.


The details of these awards are shown below.


Performance Share Plan

Under the terms of the GlaxoSmithKline Performance Share Plan, contingent awards are granted over a designated number of Ordinary shares or American Depository Shares (ADSs), with the percentage of awards ultimately vesting depending on performance. The performance condition applies over a three-year measurement period, which commenced on 1 January 2008 and will end on 31 December 2010.


The performance condition for these awards compares the Total Shareholder Return (TSR) of GSK's shares with the TSR of the shares of 14 comparator companies over the three-year period. No awards will vest if GSK delivers returns which, when ranked against these companies, rank below the median.  If GSK delivers returns which rank at the median, 35% of the award will vest.  Vesting increases on a sliding scale with 100% of the award vesting where the Company is ranked first or second when compared to the comparator group.


TSR is measured on a pro-rata basis. Where the Company's performance falls between two of the comparator companies, the exact level of vesting will be determined by the actual relative level of TSR rather than simple ranking. To the extent that an award does not vest, it lapses.


The companies in the comparator group are Abbott Laboratories, AstraZeneca, Amgen, Bristol-Myers Squibb, Eli Lilly & Co, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Takeda Pharmaceutical Company and Wyeth.


The individuals in the table below, who are either an Executive Director or Person Discharging Managerial Responsibility (PDMR), were each granted an award under the terms of the GlaxoSmithKline Performance Share Plan as set out belowThe awards were granted over the Company's 25p Ordinary shares.


Dividends accrue on the shares during the vesting period and vest to the extent that shares vest.


  Number of Ordinary shares potentially vesting



Less than median

Equal to median

Equal to 7th position

Equal to 6th position

Equal to 5th position

Equal to 4th position

Equal to 3rd position

Equal to or above 2nd  position

Mr A P Witty*

Nil

21,700

31,000

37,200

43,400

49,600

55,800

62,000

Mr S A Hussain

Nil

15,721

22,459

26,950

31,442

35,934

40,425

44,917


* denotes an Executive Director


The vesting of these awards is subject to the Remuneration Committee having determined that the performance conditions have been satisfied.



Share Option Plan

Under the terms of the GlaxoSmithKline Share Option Plan, share options allow the holder to buy Ordinary shares or ADSs at a future date at a price determined by reference to the market price of shares at the time of grant. The ultimate number of share options that become exercisable depends on GSK's earnings per share (EPS) growth over the performance period. EPS is measured over the three financial years that started on 1 January 2008 and end on 31 December 2010. To the extent that options under the GlaxoSmithKline Share Options Plan do not vest at the end of this period, they will lapse.


The performance condition compares the compound annual increase in the Company's EPS with the increase in the Retail Price Index (RPI) over the performance period compared to the base year (the financial year ended 31 December 2007). No options vest unless the Company's EPS increase exceeds RPI by 3% per annum. 50% of the share options vest for an EPS increase of 3% p.a. in excess of RPI, with increasing vesting up to 100% for an increase of 6% p.a. or more in excess of RPI.


Vesting increases on a straight-line basis for EPS performance between the hurdles set out in the tables below.


The individuals in the table below, who are either an Executive Director or a PDMR, were each granted an award under the terms of the GlaxoSmithKline Share Option Plan as set out below with an exercise price of £12.205The options were granted over the Company's 25p Ordinary shares. 


Number of Ordinary shares potentially vesting



Less than RPI +3%

RPI +3%

RPI +4%

RPI +5%

RPI +6% or more

Mr A P Witty*

Nil

72,500

96,667

120,833

145,000

Mr S A Hussain

Nil

51,771

69,028

86,285

103,542


* denotes an Executive Director


The vesting of these options is subject to the Remuneration Committee having determined that the performance conditions have been satisfied.


The Company, Directors and Persons Discharging Managerial Responsibility were advised of these transactions on 23 July 2008.


This notification is made in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).


S M Bicknell

Company Secretary


24 July 2008



Enquiries:



UK Media enquiries:                              Philip Thomson       (020) 8047 5502

              Alice Hunt                (020) 8047 5502

              Gwenan White        (020) 8047 5502


US Media enquiries:                              Nancy Pekarek       (215) 751 7709

              Mary Anne Rhyne   (919) 483 2839


European Analyst/Investor enquiries:   David Mawdsley     (020) 8047 5564

              Sally Ferguson       (020) 8047 5543

              Gary Davies           (020) 8047 5503


US Analyst/ Investor enquiries:             Frank Murdolo        (215) 751 7002

              Tom Curry              (215) 751 5419


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSDZLFLVDBBBBF

Companies

GSK (GSK)
UK 100

Latest directors dealings